JP2002525280A - ５−ｈｔ２レセプター活性を有するインダゾール誘導体 - Google Patents

５−ｈｔ２レセプター活性を有するインダゾール誘導体

Info

Publication number
JP2002525280A
JP2002525280A JP2000571048A JP2000571048A JP2002525280A JP 2002525280 A JP2002525280 A JP 2002525280A JP 2000571048 A JP2000571048 A JP 2000571048A JP 2000571048 A JP2000571048 A JP 2000571048A JP 2002525280 A JP2002525280 A JP 2002525280A
Authority
JP
Japan
Prior art keywords
compound
disorder
hydrogen
formula
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000571048A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002525280A5 (enExample
Inventor
デイビッド レジナルド アダムス，
ジョナサン マーク ベントレイ，
ジョナサン リチャード アンソニー ロッフェイ，
リチャード ジョン ハムリン，
アシュレイ ロジャー ジョージ，
Original Assignee
バーナリス リサーチ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バーナリス リサーチ リミテッド filed Critical バーナリス リサーチ リミテッド
Publication of JP2002525280A publication Critical patent/JP2002525280A/ja
Publication of JP2002525280A5 publication Critical patent/JP2002525280A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2000571048A 1998-09-01 1999-09-01 ５−ｈｔ２レセプター活性を有するインダゾール誘導体 Pending JP2002525280A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9819032.5 1998-09-01
GBGB9819032.5A GB9819032D0 (en) 1998-09-01 1998-09-01 Chemical compounds IV
PCT/GB1999/002875 WO2000012481A2 (en) 1998-09-01 1999-09-01 Indazole derivatives with 5-ht2 receptor activity________________

Publications (2)

Publication Number Publication Date
JP2002525280A true JP2002525280A (ja) 2002-08-13
JP2002525280A5 JP2002525280A5 (enExample) 2006-10-26

Family

ID=10838164

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000571048A Pending JP2002525280A (ja) 1998-09-01 1999-09-01 ５−ｈｔ２レセプター活性を有するインダゾール誘導体

Country Status (10)

Country Link
US (1) US6552062B1 (enExample)
EP (1) EP1129078B1 (enExample)
JP (1) JP2002525280A (enExample)
AT (1) ATE320419T1 (enExample)
AU (1) AU5636799A (enExample)
CA (1) CA2341612A1 (enExample)
DE (1) DE69930397T2 (enExample)
ES (1) ES2260931T3 (enExample)
GB (1) GB9819032D0 (enExample)
WO (1) WO2000012481A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9820767D0 (en) * 1998-09-23 1998-11-18 Cerebrus Ltd Chemical compounds VIII
GB9902047D0 (en) * 1999-01-29 1999-03-17 Cerebrus Ltd Chemical compounds XI
US6956036B1 (en) 2000-03-17 2005-10-18 Alcon, Inc. 6-hydroxy-indazole derivatives for treating glaucoma
PL358481A1 (en) * 2000-03-17 2004-08-09 Alcon Inc. 6-hydroxy-indazole derivatives for treating glaucoma
CA2428905A1 (en) 2000-11-20 2002-05-23 Biovitrum Ab PIPERAZINYLPYRAZINE COMPOUNDS FOR USE AS ANTAGONISTS OF THE SEROTONIN 5-HT2 RECEPTOR
SE0004245D0 (sv) 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
WO2002059082A2 (en) 2000-12-20 2002-08-01 Bristol-Myers Squibb Pharma Company Aryl and aminoaryl substituted serotonin receptor agonist and antagonist ligands
AU2002360819A1 (en) * 2001-12-28 2003-07-24 Bayer Corporation Cyclohexano- and cycloheptapyrazole derivative compounds, for use in diseases associated with the 5-ht2c receptor
TW200400177A (en) * 2002-06-04 2004-01-01 Wyeth Corp 1-(Aminoalkyl)-3-sulfonylindole and-indazole derivatives as 5-hydroxytryptamine-6 ligands
AU2003243089B2 (en) 2002-06-19 2010-01-07 Biovitrum Ab (Publ) Novel compounds, their use and preparation
CL2004000826A1 (es) 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
GB0314967D0 (en) * 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
EP1792629A4 (en) 2004-08-25 2010-08-25 Takeda Pharmaceutical MEANS FOR THE PREVENTION / TREATMENT OF STRESS-RELATED HARNINE INCONTINENCE AND PRECAUTIONARY METHOD FOR THIS
EP2727585A1 (en) 2006-05-16 2014-05-07 Takeda Pharmaceutical Company Limited In-vivo screening method
EP2216023A4 (en) 2007-11-15 2013-03-13 Takeda Pharmaceutical CONDENSED PYRIDINE DERIVATIVE AND ITS USE
JPWO2011071136A1 (ja) 2009-12-11 2013-04-22 アステラス製薬株式会社 線維筋痛症治療剤
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
JPWO2019131902A1 (ja) 2017-12-27 2020-12-10 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0232059A (ja) * 1988-07-18 1990-02-01 Kyowa Hakko Kogyo Co Ltd インダゾール誘導体
US5187166A (en) * 1990-07-31 1993-02-16 Nisshin Flour Milling Co., Ltd. Azabicyclo derivatives and their use as antiemetics
TW270114B (enExample) * 1993-10-22 1996-02-11 Hoffmann La Roche
JPH08225535A (ja) * 1994-11-15 1996-09-03 Dai Ichi Seiyaku Co Ltd インダゾール誘導体
WO1998030548A1 (en) * 1997-01-13 1998-07-16 Yamanouchi Pharmaceutical Co., Ltd. 5-HT2c RECEPTOR AGONISTS AND AMINOALKYLINDAZOLE DERIVATIVES

Also Published As

Publication number Publication date
WO2000012481A3 (en) 2000-06-08
ATE320419T1 (de) 2006-04-15
EP1129078A2 (en) 2001-09-05
GB9819032D0 (en) 1998-10-28
WO2000012481A2 (en) 2000-03-09
CA2341612A1 (en) 2000-03-09
AU5636799A (en) 2000-03-21
DE69930397D1 (de) 2006-05-11
EP1129078B1 (en) 2006-03-15
ES2260931T3 (es) 2006-11-01
DE69930397T2 (de) 2006-11-30
US6552062B1 (en) 2003-04-22

Similar Documents

Publication Publication Date Title
JP4047723B2 (ja) インドリン誘導体、および５−ｈｔ２受容体リガンドとしてのその使用
ES2228588T3 (es) Derivados de indol, procedimientos para su preparacion, composiciones farmaceuticas que los contienen y su aplicacion en medicina.
US7145009B2 (en) Pirazino(aza)indole derivatives
JP2002523491A (ja) ５−ｈｔ２ｂおよび／または５−ｈｔ２ｃレセプターリガンドとしてのインドール誘導体
US6365598B1 (en) Pyrroloquinolines for treatment of obesity
JP3828422B2 (ja) 新規アザインドリル誘導体
EP1109813B1 (en) Pyrroloindoles, pyridoindoles and azepinoindoles as 5-ht2c agonists
US6552062B1 (en) Indazole derivatives with 5-HT2 receptor activity
US7173056B2 (en) Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands
WO2000012482A2 (en) Indazole derivatives with 5-ht2 receptor activity
AU2002305732B2 (en) Pyranoindazoles and their use for the treatment of glaucoma
WO2000017170A2 (en) N1-substituted benzopyrazoles as inhibitors of 5-ht2 receptors
HK1034967B (en) Pyrroloindoles, pyridoindoles and azepinoindoles as 5-ht2c agonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060830

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091001

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20091007

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100304